Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 30;13(1):455–468. doi: 10.1080/21655979.2021.2009410

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 5. — The anti-tumor effect of co-treatment of reversine and miR-21-5p inhibitor on HBC cells by targeting SPRY2. (a) 105 common genes were overlapped from starBase and GSE124646. starBase, a tool for predicting the targets of miR-21-5p. GSE124646, a mRNA microarray for screening the downregulated genes in HBC samples. (b) Seven genes were identified to be related to cell proliferation and cell migration by STRING analysis. (c) The negative correlation between SPRY2 and miR-21-5p in BRCA samples by starBase analysis. BRCA, breast invasive carcinoma. (d) starBase predicted the binding sites between SPRY2 3ʹUTR and miR-21-5p. (e) Luciferase assay identified the target relationship between SPRY2 3ʹUTR and miR-21-5p. (f) SPRY2 expression reduced in tumor samples compared with adjacent normal samples. (g) The negative correlation between SPRY2 and miR-21-5p in tumor samples by Pearson’s correlation analysis. (h) The upregulation of SPRY2 in HBC cells treated with reversine. ** P < 0.001 compared to 0 μM group. (i) The upregulation of SPRY2 in HBC cells treated with reversine and miR-21-5p inhibitor. ** P < 0.001 compared to Blank group.